Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)

Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
Enrolling By Invitation
18-99 years
All
Phase 1
1 participants needed
1 Location

Brief description of study

This is a Phase 1, multiple-dose, ascending dose-escalation and expansion study of XmAb22841, both as a monotherapy and in combination with pembrolizumab. The study is designed in 2 parts, Part A and Part B. Part A is a 3 + 3 dose escalation designed to assess both XmAb22841 administered as a single agent as well as in combination with pembrolizumab. Part B will assess the MTD/RD determined in Part A.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: solid tumors
  • Age: Between 18 Years - 99 Years
  • Gender: All

Male or Female Age 18 or older Adequate archival tumor

Updated on 01 Aug 2024. Study ID: 833002
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research